These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 24838991)
1. Rilpivirine resistance and the dangerous liaisons with substitutions at position 184 among patients infected with HIV-1: analysis from a national drug-resistance database (ARCA). Rossotti R; Fonte L; Meini G; Maggiolo F; Zazzi M; Rusconi S; J Med Virol; 2014 Sep; 86(9):1459-66. PubMed ID: 24838991 [TBL] [Abstract][Full Text] [Related]
3. [Resistance profile of rilpivirine]. Imaz A; García F; di Yacovo S; Llibre JM Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():36-43. PubMed ID: 24252532 [TBL] [Abstract][Full Text] [Related]
4. Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine. Picchio GR; Rimsky LT; Van Eygen V; Haddad M; Napolitano LA; Vingerhoets J Antivir Ther; 2014; 19(8):819-23. PubMed ID: 24704709 [TBL] [Abstract][Full Text] [Related]
5. Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response. Vingerhoets J; Rimsky L; Van Eygen V; Nijs S; Vanveggel S; Boven K; Picchio G Antivir Ther; 2013; 18(2):253-6. PubMed ID: 22951490 [TBL] [Abstract][Full Text] [Related]
6. 96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials. Rimsky L; Van Eygen V; Hoogstoel A; Stevens M; Boven K; Picchio G; Vingerhoets J Antivir Ther; 2013; 18(8):967-77. PubMed ID: 23714781 [TBL] [Abstract][Full Text] [Related]
7. The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness. Kulkarni R; Babaoglu K; Lansdon EB; Rimsky L; Van Eygen V; Picchio G; Svarovskaia E; Miller MD; White KL J Acquir Immune Defic Syndr; 2012 Jan; 59(1):47-54. PubMed ID: 21997204 [TBL] [Abstract][Full Text] [Related]
8. Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses. Lambert-Niclot S; Charpentier C; Storto A; Fofana DB; Soulié C; Fourati S; Visseaux B; Wirden M; Morand-Joubert L; Masquelier B; Flandre P; Calvez V; Descamps D; Marcelin AG J Antimicrob Chemother; 2013 Jun; 68(6):1237-42. PubMed ID: 23361642 [TBL] [Abstract][Full Text] [Related]
9. Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors. Xu HT; Colby-Germinario SP; Huang W; Oliveira M; Han Y; Quan Y; Petropoulos CJ; Wainberg MA Antimicrob Agents Chemother; 2013 Nov; 57(11):5649-57. PubMed ID: 24002090 [TBL] [Abstract][Full Text] [Related]
11. Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine. Xu HT; Colby-Germinario SP; Asahchop EL; Oliveira M; McCallum M; Schader SM; Han Y; Quan Y; Sarafianos SG; Wainberg MA Antimicrob Agents Chemother; 2013 Jul; 57(7):3100-9. PubMed ID: 23612196 [TBL] [Abstract][Full Text] [Related]
12. Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection. Nicot F; Saliou A; Raymond S; Sauné K; Dubois M; Massip P; Marchou B; Delobel P; Izopet J J Clin Virol; 2012 Oct; 55(2):107-13. PubMed ID: 22818969 [TBL] [Abstract][Full Text] [Related]
13. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects. Porter DP; Kulkarni R; Fralich T; Miller MD; White KL HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187 [TBL] [Abstract][Full Text] [Related]
14. Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline. Asahchop EL; Wainberg MA; Oliveira M; Xu H; Brenner BG; Moisi D; Ibanescu IR; Tremblay C AIDS; 2013 Mar; 27(6):879-887. PubMed ID: 23262501 [TBL] [Abstract][Full Text] [Related]
15. Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir/rilpivirine use. Maruapula D; Moraka NO; Bareng OT; Mokgethi PT; Choga WT; Seatla KK; Kelentse N; Koofhethille CK; Zuze BJL; Gaolathe T; Pretorius-Holme M; Makhema J; Novitsky V; Shapiro R; Moyo S; Lockman S; Gaseitsiwe S J Antimicrob Chemother; 2023 Oct; 78(10):2489-2495. PubMed ID: 37585352 [TBL] [Abstract][Full Text] [Related]
16. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine. Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807 [TBL] [Abstract][Full Text] [Related]
17. Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations. Theys K; Van Laethem K; Gomes P; Baele G; Pineda-Peña AC; Vandamme AM; Camacho RJ; Abecasis AB AIDS Res Hum Retroviruses; 2016 May; 32(5):427-33. PubMed ID: 26651266 [TBL] [Abstract][Full Text] [Related]
18. Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study. Teeranaipong P; Sirivichayakul S; Mekprasan S; Ohata PJ; Avihingsanon A; Ruxrungtham K; Putcharoen O PLoS One; 2016; 11(4):e0154221. PubMed ID: 27120449 [TBL] [Abstract][Full Text] [Related]
19. Real-life rilpivirine resistance and potential emergence of an E138A-positive HIV strain in north-eastern France. Jeulin H; Foissac M; Boyer L; Agrinier N; Perrier P; Kennel A; Velay A; Goehringer F; Henard S; Rabaud C; May T; Schvoerer E J Antimicrob Chemother; 2014 Nov; 69(11):3095-102. PubMed ID: 25006240 [TBL] [Abstract][Full Text] [Related]
20. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR]. Domingo P; Ribera E Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]